

Table S1. Number of events per study for Asians, whites, and blacks.

Study	Asian								White								Black							
	N	ACM		CVM		ESRD		N	ACM		CVM		ESRD		N	ACM		CVM		ESRD				
	# of case	mean fu	# of case	mean fu	# of case	mean fu	# of case	mean fu	# of case	mean fu	# of case	mean fu	# of case	mean fu	# of case	mean fu	# of case	mean fu	# of case	mean fu				
General Population																								
Aichi	4731	50	7.4	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-		
ARIC*	23	1	10.3	0	10.3	0	10.3	8874	1423	10.6	262	10.6	101	10.6	2537	497	10.5	132	10.5	88	10.4			
AusDiab*	-	-	-	-	-	-	-	11063	922	9.9	204	7.5	-	-	-	-	-	-	-	-	-	-		
Beaver Dam	12	0	13.5	0	13.5	-	-	4827	1536	11.6	688	11.6	-	-	1	0	14.3	0	14.3	-	-	-		
Beijing*	1559	57	3.9	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-		
CHS*	3	2	8.1	0	8.1	-	-	2476	1459	8.4	552	8.4	-	-	495	261	8.6	102	8.6	-	-			
CIRCS	11871	1597	17.0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-		
COBRA*	2872	212	4.1	95	4.1	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-		
ESTHER	-	-	-	-	-	-	-	9641	489	5.0	160	5.0	-	-	-	-	-	-	-	-	-	-		
Framingham*	-	-	-	-	-	-	-	2956	301	10.5	144	10.5	-	-	-	-	-	-	-	-	-	-		
Gubbio*	-	-	-	-	-	-	-	1681	117	10.7	-	-	-	-	-	-	-	-	-	-	-	-		
HUNT*	-	-	-	-	-	-	-	9659	2287	12.0	1144	12.0	91	12.0	-	-	-	-	-	-	-	-		
IPHS	95451	15490	14.0	4733	14.0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-		
MESA*	799	31	6.2	3	6.2	-	-	2598	121	6.4	29	6.4	-	-	1859	107	6.1	23	6.1	-	-			
MRC	-	-	-	-	-	-	-	12371	7068	6.4	2996	6.4	-	-	-	-	-	-	-	-	-	-		
NHANES III*	-	-	-	-	-	-	-	6381	1225	8.3	572	8.3	-	-	4275	476	8.5	176	8.5	-	-	-		
Ohasama	1956	279	10.4	88	10.4	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-		
Okinawa83	9599	-	-	-	-	97	16.9	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-		
Okinawa93	93216	-	-	-	-	165	6.9	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-		
PREVEND*	181	14	9.5	2	9.3	-	-	8012	617	9.7	178	9.3	-	-	84	5	9.3	2	9.1	-	-	-		
RanchoBernardo*	8	0	13.7	0	13.7	-	-	1465	547	10.5	186	10.5	-	-	1	1	13.2	1	13.2	-	-	-		
REGARDS*	-	-	-	-	-	-	-	16352	1505	5.2	-	-	52	5.2	10954	1138	4.9	-	-	136	4.9			
Severance	76201	2530	10.0	424	10.0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-		
Taiwan	515573	18433	8.1	3720	8.1	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-		
ULSAM*	-	-	-	-	-	-	-	1103	462	11.6	210	11.6	-	-	-	-	-	-	-	-	-	-		
Overall GP	814055	38696	9.2	9065	9.1	262	7.9	99459	20079	8.4	7325	8.6	244	8.4	20206	2485	6.6	436	8.6	224	5.9			
High Risk																								
ADVANCE*	4132	302	4.8	164	4.8	-	-	6264	636	4.8	327	4.8	-	-	35	2	5.0	1	5.0	-	-	-		
CARE	-	-	-	-	-	-	-	3798	333	4.8	185	4.8	-	-	132	17	4.8	12	4.8	-	-	-		
KEEP	4330	84	4.0	-	-	-	-	35715	1406	4.1	-	-	-	-	24571	647	4.3	-	-	-	-	-		
KPHawaii†	-	-	-	-	-	-	-	39884	1590	2.4	-	-	330	2.4	-	-	-	-	-	-	-	-		
MRFIT	132	62	25.3	36	25.3	3	23.5	11548	6128	25.0	2865	25.0	243	23.4	930	522	24.6	230	24.6	46	23.0			
Pima*	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-		
ZODIAC*	-	-	-	-	-	-	-	1095	455	7.9	194	7.9	-	-	-	-	-	-	-	-	-	-		
Overall HR	8594	448	4.7	200	5.4	3	23.5	98304	10548	6.0	3571	15.2	573	7.1	25668	1188	5.0	243	21.6	46	23.0			
CKD																								
AASK†	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1094	254	8.8	-	-	318	7.5			
BC CKD*	4110	1157	3.4	-	-	841	3.2	11414	3043	3.4	-	-	1968	3.2	63	11	3.1	-	-	24	2.8			
CRIB*	20	7	6.5	3	6.5	14	3.4	270	104	6.0	54	6.0	128	4.2	18	4	6.8	1	6.8	7	4.7			
GeisingerACR*	6	0	1.4	-	-	-	-	3297	449	3.6	-	-	-	-	52	3	3.5	-	-	-	-			
GeisingerDip	3	1	5.7	-	-	1	3.4	4450	1023	3.9	-	-	56	3.9	45	2	3.6	-	-	1	3.5			
GLOMMS-1ACR*	-	-	-	-	-	-	-	537	314	4.2	117	4.2	-	-	-	-	-	-	-	-	-			
GLOMMS-1PCR†	-	-	-	-	-	-	-	470	261	4.2	86	4.2	85	3.7	-	-	-	-	-	-	-			
KPNW	25	6	5.2	-	-	5	4.5	1522	663	4.5	-	-	94	4.4	52	14	4.9	-	-	5	4.7			
MASTERPLAN*	26	1	4.1	-	-	5	4.1	586	66	4.1	-	-	76	4.1	18	3	3.9	-	-	3	3.8			
MDRD†	-	-	-	-	-	-	-	1385	605	14.0	277	14.0	883	10.1	214	92	14.0	56	14.0	130	10.5			
MMKD†	-	-	-	-	-	-	-	202	-	-	-	-	71	4.0	-	-	-	-	-	-	-			
NephroTest*	-	-	-	-	-	-	-	839	-	-	-	-	125	2.6	89	-	-	-	-	-	9	2.5		
RENAAL*	252	38	3.0	19	3.0	59	2.7	735	161	3.1	99	3.1	148	2.9	230	37	3.1	21	3.1	44	2.9			
STENO	-	-	-	-	-	-	-	886	175	8.8	108	8.8	75	7.8	-	-	-	-	-	-	-	-		
Sunnybrook*	-	-	-	-	-	-	-	3385	-	-	-	-	380	2.3	-	-	-	-	-	-	-	-		
Overall CKD	4442	1210	3.4	22	3.2	925	3.2	29978	6864	4.4	741	8.3	4089	3.8	1875	420	7.6	78	8.3	541	6.6			

Abbreviations: ACM, all-cause mortality; CVM, cardiovascular mortality; ESRD, end-stage renal disease; CKD, chronic kidney disease; ACR, urine albumin-to-creatinine ratio; PCR, urine protein-to-creatinine ratio. *Studies with ACR, †Studies with PCR. Within each study any racial groups with <10 events of interest were excluded.

Table S2. Characteristics of individual studies by ethnicity for Hispanics and others.

Study	Total N	Hispanic										Other												
		% N	Age	% Female	% DM	% HTN	% Hx of CVD	% HC	% Smokin g	eGFR mean	% Alb <60	% N	Age	% Female	% DM	% HTN	% Hx of CVD	% HC	% Smokin g	eGFR mean	% Alb <60			
General Population																								
Aichi	4731	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-			
ARIC*	11441	0.06%‡	63	57%	0%	29%	0%	43%	14%	89	0%	0%	-	-	-	-	-	-	-	-	-			
AusDiab*	11179	-	-	-	-	-	-	-	-	-	-	-	1%‡	45	72%	17%	24%	6%	37%	27%	90	9%	3%	
Beaver Dam	4857	0.2%‡	55	40%	30%	50%	11%	50%	10%	95	10%	0%	0.1%‡	51	14%	0%	29%	14%	29%	29%	61	0%	0%	
Beijing*	1559	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
CHS*	2988	-	-	-	-	-	-	-	-	-	-	-	1%	76	43%	36%	64%	36%	43%	0%	65	29%	36%	
CIRCS	11871	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
COBRA*	2872	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
ESTHER	9641	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Framingham*	2956	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Gubbio*	1681	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
HUNT*	9659	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
IPHS	95451	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
MESA*	6733	22%	61	52%	18%	42%	0%	27%	14%	84	12%	6%	-	-	-	-	-	-	-	-	-	-	-	
MRC	12371	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
NHANES III*	15563	27%	41	50%	13%	21%	7%	N/A	22%	107	11%	2%	4%	44	57%	10%	21%	8%	N/A	21%	101	11%	4%	
Ohasama	1956	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Okinawa83	9599	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Okinawa93	93216	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
PREVEND*	8385	-	-	-	-	-	-	-	-	-	-	-	1%‡	43	43%	9%	24%	5%	27%	37%	93	9%	1%	
Rancho Bernardo*	1474	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
REGARDS*	27306	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Severance	76201	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Taiwan	515573	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
ULSAM*	1103	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Overall GP	940366	1%	47	51%	14%	26%	5%	27%	20%	101	12%	3%	0.1%	45	57%	11%	23%	8%	33%	272%	98	11%	4%	
Percent using ACR		100%											99%											
High Risk																								
ADVANCE*	10595	-	-	-	-	-	-	-	-	-	-	-	2%	64	38%	100%	80%	23%	60%	17%	74	41%	24%	
CARE	4098	4%	58	12%	28%	90%	100%	75%	12%	78	18%	15%	-	-	-	-	-	-	-	-	-	-	-	
KEEP	77902	12%	47	67%	28%	53%	9%	N/A	11%	94	12%	7%	5%	51	71%	35%	60%	11%	N/A	19%	88	17%	13%	
KP Hawaii†	39884	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
MRFIT	12854	1%	46	0%	5%	62%	0%	52%	53%	90	7%	2%	0.5%	44	0%	10%	63%	0%	52%	57%	88	2%	2%	
Pima*	5066	-	-	-	-	-	-	-	-	-	-	-	100%	33	56%	27%	18%	0%	6%	28%	120	20%	2%	
ZODIAC*	1095	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Overall HR	151494	6%	48	64%	28%	54%	11%	63%	12%	94	12%	7%	6%	41	62%	31%	38%	5%	8%	24%	105	19%	7%	
Percent using ACR		0%											55%											
CKD																								
AASK†	1094	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
BC CKD*	17426	008%‡	54	33%	50%	N/A	0%	N/A	17%	27	100%	93%	10%	71	44%	21%	N/A	14%	N/A	4%	36	80%	87%	
CRIB*	308	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Geisinger ACR*	3361	0.09%‡	83	67%	100%	100%	33%	33%	33%	58	0%	100%	0.09%‡	56	33%	67%	100%	0%	67%	0%	52	67%	100%	
Geisinger dipstick	4509	0.09%‡	60	75%	75%	75%	50%	50%	0%	31	25%	100%	0.2%‡	68	71%	29%	71%	29%	43%	29%	48	57%	100%	
GLOMMS-1 ACR*	537	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
GLOMMS-1 PCR†	470	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
KPNW	1627	-	-	-	-	-	-	-	-	-	-	-	2%‡	68	61%	43%	21%	54%	14%	0%	50	21%	82%	
MASTERPLAN*	636	-	-	-	-	-	-	-	-	-	-	-	0.9%‡	55	33%	50%	83%	54%	100%	17%	39	83%	83%	
MDRD†	1730	-	-	-	-	-	-	-	-	-	-	-	8%	47	47%	10%	N/A	5%	N/A	10%	40	92%	79%	
MMKD†	202	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
NephroTest*	928	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
RENAAL*	1513	18%	59	46%	100%	95%	21%	61%	16%	40	100%	94%	1%‡	56	58%	100%	89%	21%	74%	11%	37	100%	95%	
STENO*	886	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Sunnybrook*	3385	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Overall CKD	38612	1%	59	46%	97%	95%	21%	61%	16%	39	98%	86%	5%	69	45%	22%	57%	14%	46%	5%	36	80%	86%	
Percent using ACR		99%											92%											

Abbreviations: eGFR, estimated glomerular filtration rate; CKD, chronic kidney disease; ACR, urine albumin-to-creatinine ratio; PCR, urine protein-to-creatinine ratio.

*Studies with ACR, †Studies with PCR.

‡Not included in meta-analysis due to small number of events (<10) in this racial group.

□ Proportion of participants with ACR ≥30 mg/g or PCR ≥50 mg/g or dipstick protein ≥1+.

Figure S1. Crude and age-standardized distribution of eGFR and albuminuria across races in general population cohorts. Panels A (eGFR) and B (albuminuria) show crude distribution, while panels C (eGFR) and D (albuminuria) are adjusted for age by direct standardization using US NHANES III as a reference population. Green, black, and red bars denote the proportions of Asian, white, and black populations, respectively.



Figure S2. Distribution of eGFR (A and C) and albuminuria (B and D) across races in high risk (A and B) and CKD (C and D) cohorts Panels A (eGFR) and B (albuminuria) show in high risk cohorts, while panels C (eGFR) and D (albuminuria) for CKD cohorts. Green, black, and red bars denote the proportions of Asian, white, and black populations, respectively.









Figure S3. Absolute risk overall of all-cause mortality (A and B), cardiovascular mortality (C and D), and ESRD (E and F) in general population cohorts.




Panels A, C, and E show the unadjusted for age meta-regression analyses and panels B, D, and F show the results adjusted for age.

Figure S4. Association of ACR by ethnicity with all-cause mortality (A) and cardiovascular mortality (B) in general population cohorts




The shaded area or whiskers represent 95% CIs. The reference (diamond) is ACR 5 mg/g. Dots represent statistically significant points. HRs were adjusted for age, sex, smoking, systolic blood pressure, history of cardiovascular disease, diabetes, serum total cholesterol concentration, body mass index, and eGFR splines. Model does not converge for ESRD in general population with ACR (only 2 studies with multiple ethnicities and ESRD as an outcome)

Figure S5. Association of eGFR by ethnicity with all-cause mortality (A) and cardiovascular mortality (B) in high risk cohorts




The shaded area or whiskers represent 95% CIs. The reference (diamond) is eGFR 95 mL/min/1.73m². Dots represent statistically significant points. HRs were adjusted for age, sex, smoking, systolic blood pressure, history of cardiovascular disease, diabetes, serum total cholesterol concentration, body mass index, and albuminuria. Model does not converge for ESRD in High Risk Population (only 2 studies with multiple ethnicities and ESRD as an outcome).

Figure S6. Association of eGFR by ethnicity with all-cause mortality (A), cardiovascular mortality (B), and ESRD (C) in CKD cohorts




The shaded area or whiskers represent 95% CIs. The reference (diamond) is eGFR 50 mL/min/1.73m². Dots represent statistically significant points. HRs were adjusted for age, sex, smoking, systolic blood pressure, history of cardiovascular disease, diabetes, serum total cholesterol concentration, body mass index, and albuminuria.

Figure S7. Association of ACR by ethnicity with all-cause mortality (A) and cardiovascular mortality (B) in high risk cohorts



The shaded area or whiskers represent 95% CIs. The reference (diamond) is ACR 5 mg/g. Dots represent statistically significant points. HRs were adjusted for age, sex, smoking, systolic blood pressure, history of cardiovascular disease, diabetes, serum total cholesterol concentration, body mass index, and eGFR splines.

Figure S8. Association of ACR/PCR by ethnicity with all-cause mortality (A), cardiovascular mortality (B), and ESRD (C) in chronic kidney disease cohorts



The shaded area or whiskers represent 95% CIs. The reference (diamond) is ACR 100 mg/g. Dots represent statistically significant points. HRs were adjusted for age, sex, smoking, systolic blood pressure, history of cardiovascular disease, diabetes, serum total cholesterol concentration, body mass index, and eGFR splines.

Figure S9. Forest plot across general population studies by grouping of Asian, white, black at eGFR 45-59 category and albuminuria 30-299 category for all-cause mortality




Figure S10. Forest plot across general population studies by grouping of Asian, white, black at eGFR 45-59 category and albuminuria 30-299 category for cardiovascular mortality




Figure S11. Forest plot across general population studies by grouping of Asian, white, black at eGFR 45-59 category and albuminuria 30-299 category for end-stage renal disease




Figure S12. Relative risk of all-cause and cardiovascular mortality according to eGFR and ACR/dipstick categories in whites, Asian, and blacks in high risk cohorts

eGFR	Asian					White					Black				
	ACR/Dipstick					ACR/Dipstick					ACR/Dipstick				
	<10 / Dip " "	10-29 / Dip " ± "	30-299 / Dip "1+ "	300+ / Dip "≥2+ "	1.01	<10 / Dip " "	10-29 / Dip " ± "	30-299 / Dip "1+ "	300+ / Dip "≥2+ "	1.23	<10 / Dip " "	10-29 / Dip " ± "	30-299 / Dip "1+ "	300+ / Dip "≥2+ "	1.08
All-cause mortality															
>105	0.96 (0.31, 2.96)	2.40 (0.85, 6.77)	3.31 (0.98, 11.15)	4.10 (1.14, 14.72)	1.01 (0.58, 9.91)	1.26 (1.12, 1.42)	1.68 (0.78, 3.62)	2.58 (1.25, 5.32)	2.87 (0.75, 10.93)	1.23 (0.94, 1.62)	1.15 (0.77, 1.71)	1.18 (0.83, 1.68)	2.94 (1.92, 4.51)	2.72 (1.7, 4.3)	1.08 (0.9, 1.3)
90-104	REF	1.61 (0.77, 3.38)	1.54 (0.82, 2.89)	10.56 (0.9, 123.47)		REF	1.22 (1, 1.48)	1.85 (1.55, 2.21)	2.48 (1.52, 4.06)		REF	1.30 (0.94, 1.79)	1.82 (0.79, 4.21)	2.51 (0.49, 12.96)	
75-89	1.10 (0.53, 2.27)	1.08 (0.61, 1.9)	2.14 (1.16, 3.96)	8.06 (3.69, 17.6)	1.03 (0.74, 1.42)	0.92 (0.87, 0.98)	1.09 (0.99, 1.21)	1.58 (1.13, 2.22)	2.75 (1.52, 5)	0.93 (0.88, 0.98)	0.98 (0.65, 1.49)	0.99 (0.56, 1.77)	1.49 (0.51, 4.38)	4.87 (2.36, 10.08)	0.95 (0.77, 1.18)
60-74	1.41 (0.84, 2.38)	1.77 (0.89, 3.5)	2.33 (1.31, 4.13)	7.20 (3.1, 16.73)	1.36 (1.01, 1.82)	0.91 (0.84, 0.98)	1.14 (0.87, 1.49)	1.86 (1.41, 2.45)	3.26 (2.08, 5.11)	0.99 (0.87, 1.13)	0.96 (0.52, 1.78)	1.44 (0.98, 2.12)	3.53 (2.11, 5.93)	2.92 (0.56, 15.15)	0.96 (0.6, 1.54)
45-59	0.95 (0.38, 2.42)	1.72 (0.52, 5.71)	4.87 (2.37, 8.03)	8.47 (2.31, 12.96)	1.52 (1.06, 2.18)	1.24 (1.07, 1.43)	1.87 (1.03, 1.82)	2.59 (2.12, 3.15)	3.25 (1.96, 5.4)	1.20 (1.08, 1.33)	1.55 (0.96, 2.49)	3.49 (0.87, 13.97)	4.16 (2.49, 6.96)	5.24 (2.45, 11.22)	1.62 (1.24, 2.12)
30-44	1.21 (0.16, 9.32)	3.84 (1.65, 8.95)	6.84 (3.42, 13.67)	9.83 (4, 24.16)	2.03 (0.65, 6.34)	1.68 (1.28, 2.22)	2.31 (1.8, 2.95)	3.26 (2.59, 4.1)	7.03 (4.24, 11.68)	1.58 (1.37, 1.83)	2.65 (1.32, 5.32)	3.31 (1.91, 5.72)	3.69 (2.01, 6.77)	8.08 (3.84, 17.01)	1.97 (1.41, 2.76)
15-29			15.31 (5.08, 46.09)	3.94 (0.35, 44.91)	3.50 (1.49, 8.2)	4.44 (1.8, 10.99)	3.36 (2.22, 5.08)	4.35 (3.25, 5.83)	8.25 (5.23, 13.07)	2.24 (1.87, 2.69)	5.14 (1.53, 17.2)	7.44 (3.19, 17.34)	5.80 (2.89, 11.64)	5.22 (2.12, 12.88)	2.34 (1.47, 3.73)
<15		24.78 (3.18, 192.87)	55.50 (8.27, 372.57)	35.05 (5.46, 224.96)	6.25 (2.07, 18.86)			6.51 (3.17, 13.23)	16.66 (4.6, 60.37)	3.97 (1.56, 10.07)			9.10 (2.73, 30.34)	25.63 (12.49, 52.6)	5.33 (2.87, 9.91)
	1.28 (0.98, 1.68)		2.06 (1.56, 2.71)	4.07 (2.8, 5.91)			1.23 (1.1, 1.37)	1.84 (1.58, 2.13)	2.82 (1.93, 4.11)			1.15 (0.99, 1.34)	1.64 (0.96, 2.8)	2.81 (1.94, 4.07)	
CV mortality															
>105	0.47 (0.05, 4.17)	1.14 (0.14, 9.48)	3.29 (0.92, 11.77)	3.27 (0.56, 19.2)	0.44 (0.06, 3.2)	1.16 (0.97, 1.4)	3.31 (0.67, 16.36)	2.92 (1.08, 7.86)	1.47 (0.37, 5.88)	1.16 (0.98, 1.37)	1.06 (0.72, 1.56)	1.10 (0.54, 2.27)	2.94 (1.25, 6.92)	5.57 (1.71, 18.2)	1.16 (0.83, 1.62)
90-104	REF	1.36 (0.6, 3.08)	1.52 (0.6, 3.8)	4.12 (1.02, 16.61)		REF	1.12 (0.94, 1.34)	1.64 (0.99, 2.72)	2.51 (0.98, 6.41)		REF	1.31 (0.69, 2.47)	1.16 (0.41, 3.24)	1.71 (0.45, 6.54)	
75-89	0.95 (0.21, 4.27)	0.88 (0.27, 2.91)	2.71 (1.05, 6.98)	15.75 (5.92, 41.91)	0.92 (0.27, 3.07)	1.02 (0.71, 1.46)	1.16 (0.97, 1.39)	1.65 (1.09, 2.48)	2.82 (0.86, 9.21)	0.97 (0.85, 1.1)	0.93 (0.63, 1.38)	0.76 (0.36, 1.63)	1.27 (0.14, 11.61)	7.30 (2.23, 23.91)	0.98 (0.69, 1.38)
60-74	1.00 (0.28, 3.62)	1.73 (0.74, 4.03)	3.57 (1.6, 7.93)	9.62 (2.01, 46.01)	1.39 (0.69, 2.78)	0.93 (0.83, 1.05)	1.19 (0.76, 1.88)	2.10 (1.54, 2.86)	3.30 (1.79, 6.1)	0.97 (0.84, 1.12)	0.75 (0.41, 1.38)	1.78 (0.7, 4.55)	3.69 (1.13, 12.01)	1.22 (0.25, 6.06)	0.64 (0.18, 2.36)
45-59	0.41 (0.05, 3.48)	1.28 (0.32, 5.16)	4.96 (1.9, 12.9)	8.59 (2.58, 28.81)	1.71 (0.98, 3.01)	1.35 (0.83, 2.2)	1.51 (0.99, 2.28)	4.09 (2.58, 6.5)	3.35 (1.92, 5.83)	1.40 (1.04, 1.88)	2.45 (0.58, 10.39)	4.14 (0.09, 181.98)	4.14 (0.65, 35.85)	2.96 (0.16, 225.9)	1.22 (0.06, 138.16)
30-44	2.90 (0.35, 24.26)	3.47 (0.68, 17.75)	10.68 (3.77, 30.26)	16.64 (4.66, 59.47)	2.19 (2.19, 7.79)	1.85 (0.57, 6.05)	5.14 (2.56, 10.34)	4.43 (2.25, 8.73)	12.85 (2.35, 70.24)	2.20 (1.46, 3.3)			5.95 (0.16, 225.9)	2.96 (0.06, 138.16)	
15-29			6.37 (0.75, 54.19)		2.36 (0.32, 17.65)	201.51 (33.23, 3070.34)	9.35 (2.14, 40.84)	8.33 (3.17, 21.85)	6.06 (1.17, 55.35)	3.83 (1.15, 12.78)					
<15		1.11 (0.71, 1.72)	2.27 (1.5, 3.43)	11.01 (1.72, 70.31)			1.27 (1.02, 1.57)	1.88 (1.46, 2.42)	2.45 (1.84, 3.25)			1.15 (0.8, 1.65)	0.90 (0.13, 6.41)	3.34 (1.84, 6.08)	

Each number represents a pooled hazard ratio from meta-analysis adjusted for covariates and compared with the reference cell (REF) within each race. Bold numbers indicate statistical significance at P<0.05. Color shading indicates the strength of association (approximately one quarter of all cells are shaded in each color; Green: low; yellow: mild; orange: moderate; red: high). All hazard ratios for blacks and Asians are compared with those for whites for interaction using meta-regression, and stars (*) indicate a significant interaction at P<0.05.

Figure S13. Relative risk of all-cause and cardiovascular mortality according to eGFR and ACR/dipstick categories in whites, Asian, and blacks in chronic kidney disease cohorts

eGFR	Asian					White					Black				
	ACR/Dipstick					ACR/Dipstick					ACR/Dipstick				
	<30 / Dip "- / ±"	30-299 / Dip "1+"	300-999 / Dip "2+"	1000+ / Dip "≥3+"		<30 / Dip "- / ±"	30-299 / Dip "1+"	300-999 / Dip "2+"	1000+ / Dip "≥3+"		<30 / Dip "- / ±"	30-299 / Dip "1+"	300-999 / Dip "2+"	1000+ / Dip "≥3+"	
All-cause mortality															
>75	1.68 (0.58, 4.83)	2.05 (0.92, 4.55)	1.16 (0.16, 8.62)	3.66 (0.86, 15.53)	1.46 (0.84, 2.52)	0.61 (0.31, 1.18)	1.53 (1.09, 2.15)	1.18 (0.47, 2.98)	1.90 (0.98, 3.68)	0.85 (0.52, 1.39)		0.55 (0.06, 4.94)	0.82 (0.09, 7.32)	1.10 (0.12, 9.74)	0.50 (0.15, 1.67)
45-74	REF	1.42 (0.86, 2.34)	1.53 (0.77, 3.04)	2.02 (1.08, 3.75)		REF	1.37 (1.16, 1.6)	1.83 (1.45, 2.3)	2.21 (1.64, 2.97)		REF	1.74 (1.21, 2.52)	2.29 (1.27, 4.13)	2.19 (0.93, 5.14)	
30-44	1.35 (0.85, 2.16)	2.07 (1.36, 3.17)	2.57 (1.58, 4.18)	3.14 (1.95, 5.06)	1.50 (1.2, 1.88)	1.41 (1.27, 1.57)	1.98 (1.73, 2.27)	1.94 (1.54, 2.46)	2.93 (2.02, 4.26)	1.38 (1.24, 1.53)	1.44 (0.36, 5.76)	2.15 (1.44, 3.22)	3.65 (1.03, 12.91)	2.74 (0.56, 13.49)	1.44 (0.94, 2.2)
15-29	2.98 (1.89, 4.71)	3.53 (2.33, 5.34)	4.86 (3.17, 7.46)	4.43 (2.86, 6.84)	2.58 (2.07, 3.22)	1.99 (1.7, 2.32)	2.73 (2.33, 3.2)	3.19 (2.7, 3.77)	4.04 (3.42, 4.78)	2.00 (1.76, 2.27)	1.76 (0.75, 4.17)	2.48 (1.56, 3.94)	1.62* (0.93, 2.8)	3.00 (0.95, 9.47)	1.20* (0.89, 1.63)
<15	4.30 (1.93, 9.55)	4.57 (2.78, 7.51)	7.38 (4.64, 11.74)	8.70 (5.39, 14.02)	4.01 (3.08, 5.21)	2.68 (1.69, 4.24)	4.38 (3.5, 5.48)	4.48 (3.54, 5.67)	4.81 (3.66, 6.31)	2.37 (1.73, 3.24)		3.69 (0.95, 14.25)	9.21 (2.08, 40.89)	11.18 (1.63, 76.89)	3.53 (1.75, 7.11)
		1.31 (1.1, 1.57)	1.76 (1.44, 2.15)	1.85 (1.5, 2.28)			1.44 (1.33, 1.55)	1.64 (1.46, 1.84)	2.05 (1.73, 2.44)			1.65 (1.25, 2.19)	1.97 (1.35, 2.87)	2.56 (1.6, 4.1)	
CVM															
>75						0.36 (0.14, 0.94)	1.55 (0.67, 3.59)	1.00 (0.37, 2.69)	1.04 (0.32, 3.38)	0.65 (0.42, 1)		0.81 (0.09, 7.69)			0.26 (0.03, 1.96)
45-74	REF					REF	1.16 (0.66, 2.04)	2.67 (1.4, 5.06)	2.10 (1.09, 4.05)		REF	0.88 (0.26, 2.9)	0.87 (0.19, 4.04)	1.15 (0.19, 6.94)	
30-44					2.74 (0.57, 13.17)	1.84 (0.96, 3.5)	2.71 (1.57, 4.68)	1.59 (0.26, 9.83)	4.60 (1.67, 12.65)	1.35 (0.86, 2.12)	0.34 (0.04, 3.24)	1.14 (0.29, 4.5)	0.39 (0.04, 3.92)	0.84 (0.16, 4.48)	1.24 (0.45, 3.41)
15-29					6.29 (1.1, 36.04)	2.60 (0.96, 7.08)	2.76 (1.55, 4.93)	3.61 (1.96, 6.64)	2.70 (1.23, 5.93)	1.79 (1.36, 2.35)		1.09 (0.24, 5.04)	1.72 (0.49, 6.03)	2.14 (0.56, 8.1)	1.48 (0.77, 2.83)
<15							11.05 (7.38, 51.25)	3.70 (1.52, 8.99)	4.47 (2.38, 8.38)	2.47 (1.66, 3.67)		3.11 (0.66, 14.57)	9.85 (2.05, 47.4)	3.37 (0.77, 14.69)	3.97 (1.64, 9.61)
							1.52 (1.11, 2.07)	1.80 (1.34, 2.4)	2.15 (1.57, 2.94)			1.60 (0.59, 4.35)	1.80 (0.61, 5.34)	1.82 (0.58, 5.73)	
ESRD															
>75	1.21 (0.14, 10.88)	1.67 (0.37, 7.49)	2.39 (0.43, 13.13)	2.62 (0.47, 14.45)	0.60 (0.28, 1.26)	0.47 (0.05, 4.78)	0.99 (0.42, 2.38)	1.31 (0.68, 2.53)	3.54 (0.9, 13.96)	0.66 (0.29, 1.51)	0.30 (0.04, 2.44)	0.94 (0.19, 4.6)	0.33 (0.04, 2.78)	0.68 (0.13, 3.52)	0.46 (0.19, 1.12)
45-74	REF	1.36 (0.41, 4.51)	3.66 (1.14, 11.67)	8.23 (2.92, 23.2)		REF	2.02 (1.2, 3.4)	2.91 (1.47, 5.8)	6.41 (3.67, 11.19)		REF	1.63 (0.27, 9.69)	3.91 (0.49, 30.89)	4.90 (0.85, 28.2)	
30-44	1.52 (0.46, 5.05)	4.50 (1.62, 12.49)	9.30 (3.33, 26)	15.20 (5.57, 41.48)	2.11 (1.6, 2.78)	1.98 (1.4, 2.81)	3.93 (2.05, 7.54)	5.10 (3.31, 7.85)	9.47 (5.86, 15.31)	2.23 (1.78, 2.8)	1.90 (0.4, 8.98)	4.40 (0.71, 27.36)	8.38 (1.15, 60.88)	14.79 (1.1, 199.45)	2.58 (1.77, 3.75)
15-29	2.82 (0.82, 9.65)	14.36 (5.28, 39.03)	20.98 (7.71, 57.1)	37.08 (13.75, 99.95)	5.38 (4.12, 7.03)	7.47 (3.68, 15.15)	8.56 (6.53, 11.22)	16.42 (9.39, 28.72)	42.09 (17.3, 102.43)	8.77 (6.25, 12.32)	3.25 (0.73, 14.46)	6.90 (0.64, 74.53)	20.20 (1.12, 362.91)	21.51 (0.4, 1152.44)	5.74 (2.41, 13.65)
<15	3.89 (0.43, 34.8)	21.54 (7.56, 61.37)	42.58 (15.43, 117.52)	73.32 (26.59, 202.22)	10.17 (7.44, 13.9)	3.11 (1.2, 8.06)	20.57 (12.97, 32.62)	41.17 (19.01, 89.15)	82.41 (25.99, 149.89)	34.23 (19.04, 61.54)		60.70 (3.49, 1055.93)	1.87 (0.37, 9.57)	199.90 (0.17, 230000)	19.61 (1.39, 276.35)
		3.52 (2.24, 5.54)	6.12 (3.88, 9.64)	10.69 (6.83, 16.71)			1.79 (1.4, 2.29)	2.90 (2.14, 3.94)	5.64 (3.74, 8.51)			2.10 (0.81, 5.48)	4.30 (0.86, 21.55)	6.15 (0.69, 55.08)	

Each number represents a pooled hazard ratio from meta-analysis adjusted for covariates and compared with the reference cell (REF) within each race. Bold numbers indicate statistical significance at P<0.05. Color shading indicates the strength of association (approximately one quarter of all cells are shaded in each color; Green: low; yellow: mild; orange: moderate; red: high). All hazard ratios for blacks and Asians are compared with those for whites for interaction using meta-regression, and stars (*) indicate a significant interaction at P<0.05.

Support Materials References

1. Mitsuhashi H, Yatsuya H, Matsushita K, *et al.* Uric acid and left ventricular hypertrophy in Japanese men. *Circ J* 2009; **73**: 667-672.
2. Matsushita K, Selvin E, Bash LD, *et al.* Change in estimated GFR associates with coronary heart disease and mortality. *J Am Soc Nephrol* 2009; **20**: 2617-2624.
3. White SL, Polkinghorne KR, Atkins RC, *et al.* Comparison of the Prevalence and Mortality Risk of CKD in Australia Using the CKD Epidemiology Collaboration (CKD-EPI) and Modification of Diet in Renal Disease (MDRD) Study GFR Estimating Equations: The AusDiab (Australian Diabetes, Obesity and Lifestyle) Study. *Am J Kidney Dis* 2010; **55**: 660-670.
4. Shankar A, Klein R, Klein BE. The association among smoking, heavy drinking, and chronic kidney disease. *Am J Epidemiol* 2006; **164**: 263-271.
5. Zhang L, Zuo L, Xu G, *et al.* Community-based screening for chronic kidney disease among populations older than 40 years in Beijing. *Nephrol Dial Transplant* 2007; **22**: 1093-1099.
6. Shlipak MG, Katz R, Kestenbaum B, *et al.* Rate of kidney function decline in older adults: a comparison using creatinine and cystatin C. *Am J Nephrol* 2009; **30**: 171-178.
7. Shimizu Y, Maeda K, Imano H, *et al.* Chronic kidney disease and drinking status in relation to risks of stroke and its subtypes: the Circulatory Risk in Communities Study (CIRCS). *Stroke* 2011; **42**: 2531-2537.
8. Jafar TH, Qadri Z, Hashmi S. Prevalence of microalbuminuria and associated electrocardiographic abnormalities in an Indo-Asian population. *Nephrol Dial Transplant* 2009; **24**: 2111-2116.
9. Zhang QL, Koenig W, Raum E, *et al.* Epidemiology of chronic kidney disease: results from a population of older adults in Germany. *Prev Med* 2009; **48**: 122-127.
10. Parikh NI, Hwang S-J, Larson MG, *et al.* Chronic Kidney Disease as a Predictor of Cardiovascular Disease (from the Framingham Heart Study). *Am J Cardiol* 2008; **102**: 47-53.
11. Cirillo M, Lanti MP, Menotti A, *et al.* Definition of kidney dysfunction as a cardiovascular risk factor: use of urinary albumin excretion and estimated glomerular filtration rate. *Arch Intern Med* 2008; **168**: 617-624.
12. Hallan SI, Coresh J, Astor BC, *et al.* International comparison of the relationship of chronic kidney disease prevalence and ESRD risk. *J Am Soc Nephrol* 2006; **17**: 2275-2284.
13. Noda H, Iso H, Irie F, *et al.* Low-density lipoprotein cholesterol concentrations and death due to intraparenchymal hemorrhage: the Ibaraki Prefectural Health Study. *Circulation* 2009; **119**: 2136-2145.
14. Bui AL, Katz R, Kestenbaum B, *et al.* Cystatin C and carotid intima-media thickness in asymptomatic adults: the Multi-Ethnic Study of Atherosclerosis (MESA). *Am J Kidney Dis* 2009; **53**: 389-398.
15. Roderick PJ, Atkins RJ, Smeeth L, *et al.* CKD and mortality risk in older people: a community-based population study in the United Kingdom. *Am J Kidney Dis* 2009; **53**: 950-960.
16. Astor BC, Hallan SI, Miller ER, 3rd, *et al.* Glomerular filtration rate, albuminuria, and risk of cardiovascular and all-cause mortality in the US population. *Am J Epidemiol* 2008; **167**: 1226-1234.
17. Nakayama M, Metoki H, Terawaki H, *et al.* Kidney dysfunction as a risk factor for first symptomatic stroke events in a general Japanese population--the Ohasama study. *Nephrol Dial Transplant* 2007; **22**: 1910-1915.

18. Iseki K, Ikemiya Y, Iseki C, *et al.* Proteinuria and the risk of developing end-stage renal disease. *Kidney Int* 2003; **63**: 1468-1474.
19. Iseki K, Kohagura K, Sakima A, *et al.* Changes in the demographics and prevalence of chronic kidney disease in Okinawa, Japan (1993 to 2003). *Hypertens Res* 2007; **30**: 55-62.
20. Hillege HL, Fidler V, Diercks GF, *et al.* Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. *Circulation* 2002; **106**: 1777-1782.
21. Jassal SK, Kritz-Silverstein D, Barrett-Connor E. A Prospective Study of Albuminuria and Cognitive Function in Older Adults: The Rancho Bernardo Study. *Am J Epidemiol* 2010; **171**: 277-286.
22. Howard VJ, Cushman M, Pulley L, *et al.* The reasons for geographic and racial differences in stroke study: objectives and design. *Neuroepidemiology* 2005; **25**: 135-143.
23. Kimm H, Yun JE, Jo J, *et al.* Low Serum Bilirubin Level as an Independent Predictor of Stroke Incidence: A Prospective Study in Korean Men and Women. *Stroke* 2009; **40**: 3422-3427.
24. Wen CP, Cheng TY, Tsai MK, *et al.* All-cause mortality attributable to chronic kidney disease: a prospective cohort study based on 462 293 adults in Taiwan. *Lancet* 2008; **371**: 2173-2182.
25. Ingelsson E, Sundstrom J, Lind L, *et al.* Low-grade albuminuria and the incidence of heart failure in a community-based cohort of elderly men. *Eur Heart J* 2007; **28**: 1739-1745.
26. Patel A, MacMahon S, Chalmers J, *et al.* Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. *Lancet* 2007; **370**: 829-840.
27. Tonelli M, Jose P, Curhan G, *et al.* Proteinuria, impaired kidney function, and adverse outcomes in people with coronary disease: analysis of a previously conducted randomised trial. *BMJ* 2006; **332**: 1426.
28. Jurkovitz CT, Qiu Y, Wang C, *et al.* The Kidney Early Evaluation Program (KEEP): program design and demographic characteristics of the population. *Am J Kidney Dis* 2008; **51**: S3-12.
29. Lee BJ, Forbes K. The role of specialists in managing the health of populations with chronic illness: the example of chronic kidney disease. *BMJ* 2009; **339**: b2395.
30. Ishani A, Grandits GA, Grimm RH, *et al.* Association of single measurements of dipstick proteinuria, estimated glomerular filtration rate, and hematocrit with 25-year incidence of end-stage renal disease in the multiple risk factor intervention trial. *J Am Soc Nephrol* 2006; **17**: 1444-1452.
31. Pavkov ME, Knowler WC, Hanson RL, *et al.* Predictive power of sequential measures of albuminuria for progression to ESRD or death in Pima Indians with type 2 diabetes. *Am J Kidney Dis* 2008; **51**: 759-766.
32. Bilo HJ, Logtenberg SJ, Joosten H, *et al.* Modification of diet in renal disease and Cockcroft-Gault formulas do not predict mortality (ZODIAC-6). *Diabet Med* 2009; **26**: 478-482.
33. Wright JT, Jr., Bakris G, Greene T, *et al.* Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. *JAMA* 2002; **288**: 2421-2431.
34. Levin A, Djurdjev O, Beaulieu M, *et al.* Variability and risk factors for kidney disease progression and death following attainment of stage 4 CKD in a referred cohort. *Am J Kidney Dis* 2008; **52**: 661-671.
35. Landray MJ, Thambyrajah J, McGlynn FJ, *et al.* Epidemiological evaluation of known and suspected cardiovascular risk factors in chronic renal impairment. *Am J Kidney Dis* 2001; **38**: 537-546.

36. Perkins RM, Bucaloiu ID, Kirchner HL, *et al.* GFR decline and mortality risk among patients with chronic kidney disease. *Clin J Am Soc Nephrol* 2011; **6**: 1879-1886.
37. Marks A, Black C, Fluck N, *et al.* Translating chronic kidney disease epidemiology into patient care - the individual/public health risk paradox. *Nephrol Dial Transplant* 2012.
38. Keith DS, Nichols GA, Gullion CM, *et al.* Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization. *Arch Intern Med* 2004; **164**: 659-663.
39. van Zuilen AD, Bots ML, Dulger A, *et al.* Multifactorial intervention with nurse practitioners does not change cardiovascular outcomes in patients with chronic kidney disease. *Kidney Int* 2012; **82**: 710-717.
40. Klahr S, Levey AS, Beck GJ, *et al.* The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of Diet in Renal Disease Study Group. *N Engl J Med* 1994; **330**: 877-884.
41. Kronenberg F, Kuen E, Ritz E, *et al.* Lipoprotein(a) serum concentrations and apolipoprotein(a) phenotypes in mild and moderate renal failure. *J Am Soc Nephrol* 2000; **11**: 105-115.
42. Moranne O, Froissart M, Rossert J, *et al.* Timing of onset of CKD-related metabolic complications. *J Am Soc Nephrol* 2009; **20**: 164-171.
43. Brenner BM, Cooper ME, de Zeeuw D, *et al.* Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. *N Engl J Med* 2001; **345**: 861-869.
44. Jorsal A, Tarnow L, Frystyk J, *et al.* Serum adiponectin predicts all-cause mortality and end stage renal disease in patients with type I diabetes and diabetic nephropathy. *Kidney Int* 2008; **74**: 649-654.
45. Tangri N, Stevens LA, Griffith J, *et al.* A predictive model for progression of chronic kidney disease to kidney failure. *JAMA* 2011; **305**: 1553-1559.
46. The National Institute for Health and Clinical Excellence: Chronic kidney disease: early identification and management of chronic kidney disease in adults in primary and secondary care. In (vol 2008), 2008
47. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. *Am J Kidney Dis* 2002; **39**: S1-266.
48. Shlipak MG, Sarnak MJ, Katz R, *et al.* Cystatin C and the risk of death and cardiovascular events among elderly persons. *N Engl J Med* 2005; **352**: 2049-2060.
49. Matsushita K, Selvin E, Bash LD, *et al.* Risk implications of the new CKD-EPI equation as compared to the MDRD Study equation for estimated glomerular filtration rate: the Atherosclerosis Risk in Communities (ARIC) Study. *Am J Kidney Dis* 2010; **55**: 648-659.
50. Astor BC, Levey AS, Stevens LA, *et al.* Method of Glomerular Filtration Rate Estimation Affects Prediction of Mortality Risk. *J Am Soc Nephrol* 2009; **20**: 2214-2222.
51. S201 sex and age by ethnic group, all people, geographic level: Health board - Grampian 2001 census [Internet]. In, General Register Office for Scotland, 2009